Effect of intravitreous anti–vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the protocol …
RK Maturi, AR Glassman, K Josic… - JAMA …, 2021 - jamanetwork.com
Importance The role of anti–vascular endothelial growth factor injections for the
management of nonproliferative diabetic retinopathy (NPDR) without center-involved …
management of nonproliferative diabetic retinopathy (NPDR) without center-involved …
Association of predominantly peripheral lesions on ultra-widefield imaging and the risk of diabetic retinopathy worsening over time
Importance Ultra-widefield (UWF) imaging improves the ability to identify peripheral diabetic
retinopathy (DR) lesions compared with standard imaging. Whether detection of …
retinopathy (DR) lesions compared with standard imaging. Whether detection of …
Association of ultra-widefield fluorescein angiography–identified retinal nonperfusion and the risk of diabetic retinopathy worsening over time
Importance Presence of predominantly peripheral diabetic retinopathy (DR) lesions on ultra-
widefield fluorescein angiography (UWF-FA) was associated with greater risk of DR …
widefield fluorescein angiography (UWF-FA) was associated with greater risk of DR …
Optical Coherence Tomography Angiography of Macular Perfusion Changes after Anti‐VEGF Therapy for Diabetic Macular Edema: A Systematic Review
AG Elnahry, GA Elnahry - Journal of Diabetes Research, 2021 - Wiley Online Library
Background. Diabetic macular edema (DME) is a major cause of vision loss in diabetics that
is currently mainly treated by antivascular endothelial growth factor (VEGF) agents. The …
is currently mainly treated by antivascular endothelial growth factor (VEGF) agents. The …
Review on recent trials evaluating the effect of intravitreal injections of anti-VEGF agents on the macular perfusion of diabetic patients with diabetic macular edema
AG Elnahry, AA Abdel-Kader, AE Habib… - Reviews on Recent …, 2020 - ingentaconnect.com
Background: Diabetic macular edema (DME) is a major cause of vision loss in diabetics
worldwide. Anti-vascular endothelial growth factor (anti-VEGF) agents have become the …
worldwide. Anti-vascular endothelial growth factor (anti-VEGF) agents have become the …
Topographical response of retinal neovascularization to aflibercept or panretinal photocoagulation in proliferative diabetic retinopathy: post hoc analysis of the …
S Halim, M Nugawela, U Chakravarthy… - JAMA …, 2021 - jamanetwork.com
Importance Eyes with proliferative diabetic retinopathy have a variable response to
treatment with panretinal photocoagulation (PRP) or anti–vascular endothelial growth factor …
treatment with panretinal photocoagulation (PRP) or anti–vascular endothelial growth factor …
The effect of brolucizumab on diabetic macular edema and ischemia; a real world analysis
A Chronopoulos, LK Sas, JW Holzwarth… - 2024 - researchsquare.com
Objective The response to intravitreal brolucizumab on diabetic macular edema and
macular ischemia was studied in treatment-refractory and treatment-naïve patients. Methods …
macular ischemia was studied in treatment-refractory and treatment-naïve patients. Methods …